Search

Your search keyword '"Scheding, Stefan"' showing total 339 results
Start Over Author "Scheding, Stefan"
339 results on '"Scheding, Stefan"'

19. Survival and risk of vascular complications in myelofibrosis : a population-based study from the Swedish MPN group

Author

Lindgren, Marie, Andréasson, Björn, Samuelsson, Jan, Pettersson, Helna, Enblom, Anneli, Ravn-Landtblom, Anna, Scheding, Stefan, Bentham, Carolina, Ahlstrand, Erik, Lindgren, Marie, Andréasson, Björn, Samuelsson, Jan, Pettersson, Helna, Enblom, Anneli, Ravn-Landtblom, Anna, Scheding, Stefan, Bentham, Carolina, and Ahlstrand, Erik

Abstract

Objective: To gain knowledge of underlying risk factors for vascular complications and their impact on life expectancy in myelofibrosis. Methods: From a cohort of 392 myelofibrosis patients registered in the Swedish MPN registry 58 patients with vascular complications during follow-up were identified. Patients with vascular complications were compared with both 1:1 matched controls and the entire myelofibrosis cohort to explore potential risk factors for vascular complications and their impact on survival. Results: Incidence of vascular complications was 2.8 events per 100 patient-years and the majority of complications were thrombotic. Patients with complications were significantly older and had lower hemoglobin when compared to the entire cohort. In the case–control analysis, no significant risk factor differences were observed. The major cause of death was vascular complications and median survival was significantly impaired in patients with vascular complications (48 months) compared to controls (92 months). Inferior survival in patients with vascular complications was found to be dependent on IPSS risk category in a Cox regression model. Conclusion: Vascular complications have a considerable impact on survival in MF. At diagnosis, risk assessment by IPSS does not only predict survival but is also associated with the risk of vascular complications.

Published
2022
Full Text
View/download PDF

21. Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells

Author

Rosa, Fábio F., primary, Pires, Cristiana F., additional, Kurochkin, Ilia, additional, Halitzki, Evelyn, additional, Zahan, Tasnim, additional, Arh, Nejc, additional, Zimmermannová, Olga, additional, Ferreira, Alexandra G., additional, Li, Hongzhe, additional, Karlsson, Stefan, additional, Scheding, Stefan, additional, and Pereira, Carlos-Filipe, additional

Published
2022
Full Text
View/download PDF

22. A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells

Author

von Palffy, Sofia, Landberg, Niklas, Sandén, Carl, Zacharaki, Dimitra, Shah, Mansi, Nakamichi, Naoto, Hansen, Nils, Askmyr, Maria, Lilljebjörn, Henrik, Rissler, Marianne, Karlsson, Christine, Scheding, Stefan, Richter, Johan, Eaves, Connie J., Bhatia, Ravi, Järås, Marcus, and Fioretos, Thoas

Subjects
Bone Marrow, hemic and lymphatic diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Cytokines, Humans, Antigens, CD34, Articles, Myostatin, musculoskeletal system, Hematopoietic Stem Cells, Cells, Cultured
Abstract

Aberrantly expressed cytokines in the bone marrow (BM) niche are increasingly recognized as critical mediators of survival and expansion of leukemic stem cells. To identify regulators of primitive chronic myeloid leukemia (CML) cells, we performed a high-content cytokine screen using primary CD34+ CD38low chronic phase CML cells. Out of the 313 unique human cytokines evaluated, 11 were found to expand cell numbers ≥2-fold in a 7-day culture. Focusing on novel positive regulators of primitive CML cells, the myostatin antagonist myostatin propeptide gave the largest increase in cell expansion and was chosen for further studies. Herein, we demonstrate that myostatin propeptide expands primitive CML and normal BM cells, as shown by increased colony-forming capacity. For primary CML samples, retention of CD34-expression was also seen after culture. Furthermore, we show expression of MSTN by CML mesenchymal stromal cells, and that myostatin propeptide has a direct and instant effect on CML cells, independent of myostatin, by demonstrating binding of myostatin propeptide to the cell surface and increased phosphorylation of STAT5 and SMAD2/3. In summary, we identify myostatin propeptide as a novel positive regulator of primitive CML cells and corresponding normal hematopoietic cells.

Published
2020

30. Additional file 1 of Label-free separation of neuroblastoma patient-derived xenograft (PDX) cells from hematopoietic progenitor cell products by acoustophoresis

Author

Olm, Franziska, Panse, Lena, Dykes, Josefina H., Bexell, Daniel, Laurell, Thomas, and Scheding, Stefan

Abstract

Additional file 1. Supplementary Equations. Supplementary Equation 1. In an ultrasonic standing wave field, the acoustic radiation force Fzrad acts on a particle that has a non-zero acoustic contrast factor, Φ. The magnitude of the force acting on the particle depends on the radius ɑ, κ0, ρ0, κp and ρp which represent the compressibility and density of the fluid and particle, respectively, as well as on Φ( $$\tilde{\kappa}, \tilde{\rho}$$ κ ~ , ρ ~ ), which is the acoustic contrast factor. Other parameters are the wave number (2π/λ) denoted by k, and the acoustic energy density, Eac. The acoustic radiation force also depends on z, i.e., the position of the particle along the wave propagation axis, and pa, the pressure amplitude, and c0, the speed of sound in the medium. Supplementary Equation 2. A particle in an acoustic standing wave field has a characteristic acoustophoretic mobility which is determined by the particle radius α, the viscosity of the medium η, and the acoustic contrast factor Φ. Supplementary Equations 3. Equations for the calculations of separation efficiencies (1, 2), whereby C denotes particle concentrations and V denotes the volumes of the respective center (c) and side (s) fractions. Supplementary Table. Supplementary Table 1. Primer Sequences for RT-PCR, primers were purchased from Life Technologies or TAG Copenhagen A/S (Copenhagen, Denmark). Supplementary Figures. Supplementary Figure S1. Schematic illustration of an acoustic pressure field (solid blue line) and the resulting acoustic radiation force (dashed red line) in a microchannel cross-section. Red arrows indicate the direction of Frad for particles with a positive acoustic contrast factor Φ. Supplementary Figure S2. RT-PCR calibration curve to assess the sensitivity of NBC detection for the PHOX2B, TH and DDC genes used in the study. Cq values for PDX-1 cells, PBPCs and ratios of 1:100 to 1:1,000,000 PDX:PBPCs (n = 1, mean of three technical repeats).

Published
2021
Full Text
View/download PDF

33. Highly Reduced Survival in Essential Thrombocythemia and Polycythemia Vera Patients with Vascular Complications during Follow-up

Author

Ahlstrand, Erik, Samuelsson, Jan, Lindgren, Marie, Pettersson, Helna, Liljeholm, Maria, Ravn-Landtblom, Anna, Scheding, Stefan, Andréasson, Björn, Ahlstrand, Erik, Samuelsson, Jan, Lindgren, Marie, Pettersson, Helna, Liljeholm, Maria, Ravn-Landtblom, Anna, Scheding, Stefan, and Andréasson, Björn

Abstract

OBJECTIVE: To explore the relative importance of risk factors, treatments and blood counts for the occurrence of vascular complications and their impact on life expectancy in Essential Thrombocythemia (ET) and Polycythemia Vera (PV). METHODS: Nested case-control study within the Swedish MPN registry. From a cohort of 922 ET patients and 763 PV patients, 71 ET and 81 PV cases with vascular complications were compared to matched controls. RESULTS: Incidence of vascular complications were 2.0 and 3.4 events per 100 patient-years in ET and PV, respectively. At diagnosis, no significant risk factor differences were observed between cases and controls in neither of the diseases. At the time of vascular event, ET complication cases did not differ significantly from controls but in PV, cases had significantly higher WBCs and were to a lesser extent treated with antithrombotic and cytoreductive therapy. Life expectancy was significantly decreased in both ET and PV cases compared to controls. CONCLUSIONS: The risk of vascular complications is high in both ET and PV and these complications have a considerable impact on life expectancy. The protective effect of antithrombotic and cytoreductive therapy for vascular complications in PV underscores the importance of avoiding undertreatment., Funding Agency:Regional FOU Västra Götaland County

Published
2020
Full Text
View/download PDF

40. CD105+CD90+CD13+ identifies a clonogenic subset of adventitial lung fibroblasts.

Author

Kadefors, Måns, Rolandsson Enes, Sara, Åhrman, Emma, Michaliková, Barbora, Löfdahl, Anna, Dellgren, Göran, Scheding, Stefan, and Westergren-Thorsson, Gunilla

Subjects
TISSUE remodeling, LUNG diseases, TRANSCRIPTOMES, REGENERATION (Biology)
Abstract

Mesenchymal cells are important components of specified niches in the lung, and can mediate a wide range of processes including tissue regeneration and repair. Dysregulation of these processes can lead to improper remodeling of tissue as observed in several lung diseases. The mesenchymal cells responsible remain poorly described, partially due to the heterogenic nature of the mesenchymal compartment and the absence of appropriate markers. Here, we describe that CD105+CD90+ mesenchymal cells can be divided into two populations based on their expression of CD13/aminopeptidase N (CD105+CD90+CD13− and CD105+CD90+CD13+). By prospective isolation using FACS, we show that both these populations give rise to clonogenic fibroblast-like cells, but with an increased clonogenic and proliferative capacity of CD105+CD90+CD13+ cells. Transcriptomic and spatial analysis pinpoints an adventitial fibroblast subset as the origin of CD105+CD90+CD13+ clonogenic mesenchymal cells in human lung. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells

Author

von Palffy, Sofia, primary, Landberg, Niklas, additional, Sandén, Carl, additional, Zacharaki, Dimitra, additional, Shah, Mansi, additional, Nakamichi, Naoto, additional, Hansen, Nils, additional, Askmyr, Maria, additional, Lilljebjörn, Henrik, additional, Rissler, Marianne, additional, Karlsson, Christine, additional, Scheding, Stefan, additional, Richter, Johan, additional, Eaves, Connie J., additional, Bhatia, Ravi, additional, Järås, Marcus, additional, and Fioretos, Thoas, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results